Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious and inflammatory mediated diseases. The Immuron news feed on Stock Titan aggregates company announcements, market updates and regulatory disclosures so readers can follow developments around its commercial products and clinical pipeline.
News about Immuron frequently highlights Travelan®, an over‑the‑counter immune supplement and dietary supplement based on hyper‑immune bovine antibodies that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Company updates have reported record Travelan sales in Australia and North America, marketing initiatives in retail and online channels, and clinical trial activity involving IMM‑124E, the active ingredient in Travelan, in collaboration with the Uniformed Services University.
Investors and followers can also expect coverage of pipeline milestones such as FDA interactions and clinical plans for IMM‑529, a candidate for Clostridioides difficile infection, and IMM‑986, a pre‑clinical program targeting vancomycin‑resistant enterococci. Immuron’s announcements describe pre‑clinical results, Investigational New Drug submissions and approvals, and collaborations with institutions including Naval Medical Research Command, Walter Reed Army Institute of Research and Monash University.
In addition, the news stream includes letters to shareholders, sales updates, distribution agreements such as the ProIBS® IBS product in Australia and New Zealand, and corporate communications about investor engagement initiatives. Bookmark this page to access a consolidated view of Immuron’s operational, clinical, commercial and corporate news as it is released through official channels.
Immuron (IMRN), an Australian biopharmaceutical company, announced significant board changes on May 31, 2024. Dr. Roger Aston resigned as Non-Executive Director after serving since 2012, including as Chairman until 2023. Over his tenure, Immuron advanced its commercial and clinical programs, especially in diarrhoea prevention and gut health, strengthened by its partnership with the US Military. Dr. Aston's leadership was pivotal during capital raisings and the COVID-19 pandemic. Effective June 1, 2024, Dr. Jeannie Joughin, with extensive experience in immunology and senior roles at major pharmaceutical companies, will join as a Non-Executive Director, expected to enhance Immuron's strategic and commercial direction.
Immuron , an Australian biopharmaceutical company, will be presenting at the Emerging Growth Conference on May 8, 2024. Investors, analysts, and advisors can interact with the CEO, Steven Lydeamore, during the live event. Questions can be submitted in advance or during the presentation.
Immuron announces the resignation of Non-Executive Director Stephen Anastasiou to focus on other business interests. Stephen has been with the company since 2013, contributing to the launch of Travelan® in the USA and Canadian markets and dual listing on NASDAQ (IMRN). His departure is aimed at restructuring his business commitments to spend more time with family and pursue personal interests. Immuron Chairman expresses gratitude for Stephen's marketing and clinical contributions and wishes him success in future endeavors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Immuron (IMRN)?
What is the market cap of Immuron (IMRN)?
